

Remarks

In view of the above amendments based on our telephonic conversation Applicants request withdrawal of the rejections in the Office Action dated June 7, 2007.

Claims 1, 6, 7, 9-13, 16-27, 45-46 and 49-51 are pending with claims 1, 27 and 45 being independent.


Claims 1, 27 and 45 have been amended to include the limitation of screening the powder blend through a mesh after blending but before filling in capsules. Support for such amendment could be found at several places in the specification. For example, the process described in Examples 1-5, requires the blend prepared by mixing the active ingredient – phenytoin sodium – with the inactive ingredients to be screened through a No. 30 mesh before being filled in “0” hard gelatin capsules.

The Applicants would like point out that in doing the amendments, no matter has been added.

Conclusion

As the claims have been amended per the telephonic discussion, the Examiner is urged to pass claims 1, 6, 7, 9-13, 16-27, 45-46 and 49-51 to issue. Authorization is hereby given to charge any fees or credits due in connection with this Response to Office Action to Deposit Account No. 50-0912.

Respectfully submitted,


George E. Heibel, PhD, Reg. No. 42, 648

Date: October 30, 2007

Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel: (609) 720-5334
Fax: (609) 514-9779